Skip to main content
. 2016 Aug 9;6:31391. doi: 10.1038/srep31391

Figure 4. The effect of lower concentrations of GSK2578215A on LRRK2 dephosphorylation in control and PD patient PBMCs.

Figure 4

Peripheral blood mononuclear cells isolated from control and PD patients were treated with either 0.125 μM or 0.063 μM GSK2578215A for 1 h. Resulting cell lysates were immunoblotted for LRRK2 and LRRK2 phosphorylated at Ser910 (A), Ser935 (B), Ser955 (C) and Ser973 (D). Following quantitation, phosphorylated LRRK2 was normalized to total LRRK2 and results expressed as the percentage reduction in phosphorylation compared to the non-inhibitor treated control group. Two-way ANOVA with Tukey’s post hoc test was used to determine any significant effects, defined as p < 0.05, of inhibitor or disease status on levels of phosphorylation. Data are mean ± SEM. ***p < 0.001, **p < 0.01. Representative cropped immunoblots are shown. Fuller western blots are available in Supplementary Figure 1. Sample size is 12 control and 12 PD patients.